Literature DB >> 26381407

Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy.

Chien-Chung Chang1, Giuseppe Pirozzi2, Shao-Hsuan Wen3, I-Hsin Chung3, Bau-Lin Chiu3, Simona Errico2, Monica Luongo2, Maria Luisa Lombardi2, Soldano Ferrone4.   

Abstract

Scant information is available about the molecular basis of multiple HLA class I antigen-processing machinery defects in malignant cells, although this information contributes to our understanding of the molecular immunoescape mechanisms utilized by tumor cells and may suggest strategies to counteract them. In the present study we reveal a combination of IFN-γ-irreversible structural and epigenetic defects in HLA class I antigen-processing machinery in a recurrent melanoma metastasis after immunotherapy. These defects include loss of tapasin and one HLA haplotype as well as selective silencing of HLA-A3 gene responsiveness to IFN-γ. Tapasin loss is caused by a germ-line frameshift mutation in exon 3 (TAPBP(684delA)) along with a somatic loss of the other gene copy. Selective silencing of HLA-A3 gene and its IFN-γ responsiveness is associated with promoter CpG methylation nearby site-α and TATA box, reversible after DNA methyltransferase 1 depletion. This treatment combined with tapasin reconstitution and IFN-γ stimulation restored the highest level of HLA class I expression and its ability to elicit cytotoxic T cell responses. These results represent a novel tumor immune evasion mechanism through impairing multiple components at various levels in the HLA class I antigen presentation pathway. These findings may suggest a rational design of combinatorial cancer immunotherapy harnessing DNA demethylation and IFN-γ response.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  DNA methylation; antigen presentation; immunotherapy; major histocompatibility complex (MHC); tumor immunology

Mesh:

Substances:

Year:  2015        PMID: 26381407      PMCID: PMC4646314          DOI: 10.1074/jbc.M115.676130

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  54 in total

1.  Optimization of the MHC class I peptide cargo is dependent on tapasin.

Authors:  Anthony P Williams; Chen Au Peh; Anthony W Purcell; James McCluskey; Tim Elliott
Journal:  Immunity       Date:  2002-04       Impact factor: 31.745

2.  A critical role for tapasin in the assembly and function of multimeric MHC class I-TAP complexes.

Authors:  B Ortmann; J Copeman; P J Lehner; B Sadasivan; J A Herberg; A G Grandea; S R Riddell; R Tampé; T Spies; J Trowsdale; P Cresswell
Journal:  Science       Date:  1997-08-29       Impact factor: 47.728

Review 3.  Mechanisms of MHC class I-restricted antigen processing and cross-presentation.

Authors:  Peter Cresswell; Anne L Ackerman; Alessandra Giodini; David R Peaper; Pamela A Wearsch
Journal:  Immunol Rev       Date:  2005-10       Impact factor: 12.988

Review 4.  Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions.

Authors:  Chien-Chung Chang; Michael Campoli; Soldano Ferrone
Journal:  Adv Cancer Res       Date:  2005       Impact factor: 6.242

5.  Identification of a gp100 epitope recognized by HLA-A3 restricted melanoma infiltrating lymphocytes.

Authors:  A Moreau-Aubry; J Fonteneau; N Labarriere; F Jotereau; E Houssaint; R Breathnach
Journal:  Int J Oncol       Date:  1997-04       Impact factor: 5.650

6.  Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes.

Authors:  Yun-Gyoo Lee; Inho Kim; Sung-Soo Yoon; Seonyang Park; June Won Cheong; Yoo Hong Min; Jeong-Ok Lee; Soo-Mee Bang; Hyeon Gyu Yi; Chul Soo Kim; Yong Park; Byung-Soo Kim; Yeung-Chul Mun; Chu-Myoung Seong; Jinny Park; Jae Hoon Lee; Sung-Yong Kim; Hong Ghi Lee; Yeo-Kyeoung Kim; Hyeoung-Joon Kim
Journal:  Br J Haematol       Date:  2013-02-21       Impact factor: 6.998

7.  Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products.

Authors:  N J Stam; H Spits; H L Ploegh
Journal:  J Immunol       Date:  1986-10-01       Impact factor: 5.422

8.  Soluble tapasin restores MHC class I expression and function in the tapasin-negative cell line .220.

Authors:  P J Lehner; M J Surman; P Cresswell
Journal:  Immunity       Date:  1998-02       Impact factor: 31.745

Review 9.  Tapasin-the keystone of the loading complex optimizing peptide binding by MHC class I molecules in the endoplasmic reticulum.

Authors:  F Momburg; P Tan
Journal:  Mol Immunol       Date:  2002-10       Impact factor: 4.407

10.  Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines.

Authors:  Teresa Rodríguez; Rosa Méndez; Ana Del Campo; Pilar Jiménez; Natalia Aptsiauri; Federico Garrido; Francisco Ruiz-Cabello
Journal:  BMC Cancer       Date:  2007-02-23       Impact factor: 4.430

View more
  34 in total

Review 1.  Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways.

Authors:  Xue Bai; David E Fisher; Keith T Flaherty
Journal:  Nat Rev Clin Oncol       Date:  2019-09       Impact factor: 66.675

2.  Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors.

Authors:  Tanios Bekaii-Saab; Robert Wesolowski; Daniel H Ahn; Christina Wu; Amir Mortazavi; Maryam Lustberg; Bhuvaneswari Ramaswamy; Jeffrey Fowler; Lai Wei; Jay Overholser; Pravin T P Kaumaya
Journal:  Clin Cancer Res       Date:  2019-02-25       Impact factor: 12.531

Review 3.  Immunoplasticity in cutaneous melanoma: beyond pure morphology.

Authors:  Francesca Maria Bosisio; Joost J van den Oord
Journal:  Virchows Arch       Date:  2017-01-05       Impact factor: 4.064

4.  Loss of tapasin in human lung and colon cancer cells and escape from tumor-associated antigen-specific CTL recognition.

Authors:  Yosuke Shionoya; Takayuki Kanaseki; Sho Miyamoto; Serina Tokita; Ayumi Hongo; Yasuhiro Kikuchi; Vitaly Kochin; Kazue Watanabe; Ryota Horibe; Hiroshi Saijo; Tomohide Tsukahara; Yoshihiko Hirohashi; Hiroki Takahashi; Noriyuki Sato; Toshihiko Torigoe
Journal:  Oncoimmunology       Date:  2017-01-03       Impact factor: 8.110

5.  Cytosolic Processing Governs TAP-Independent Presentation of a Critical Melanoma Antigen.

Authors:  Nathalie Vigneron; Violette Ferrari; Benoît J Van den Eynde; Peter Cresswell; Ralf M Leonhardt
Journal:  J Immunol       Date:  2018-08-22       Impact factor: 5.422

Review 6.  Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion.

Authors:  Suchit Jhunjhunwala; Christian Hammer; Lélia Delamarre
Journal:  Nat Rev Cancer       Date:  2021-03-09       Impact factor: 60.716

Review 7.  Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack.

Authors:  Fade Mahmoud; Bradley Shields; Issam Makhoul; Nathan Avaritt; Henry K Wong; Laura F Hutchins; Sara Shalin; Alan J Tackett
Journal:  Cancer Biol Ther       Date:  2017-05-17       Impact factor: 4.742

Review 8.  Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells.

Authors:  Fernando Concha-Benavente; Raghvendra Srivastava; Soldano Ferrone; Robert L Ferris
Journal:  Oral Oncol       Date:  2016-06-02       Impact factor: 5.337

Review 9.  Acquired resistance to cancer immunotherapy.

Authors:  Arianna Draghi; Christopher Aled Chamberlain; Andrew Furness; Marco Donia
Journal:  Semin Immunopathol       Date:  2018-07-02       Impact factor: 9.623

10.  Defective HLA class I antigen processing machinery in cancer.

Authors:  Lei Cai; Theodoros Michelakos; Teppei Yamada; Song Fan; Xinhui Wang; Joseph H Schwab; Cristina R Ferrone; Soldano Ferrone
Journal:  Cancer Immunol Immunother       Date:  2018-02-27       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.